title: Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
authors.affiliation: a Division of Oncology, Washington University School of Medicine , St. Louis , MO , USA.
authors.forename: Armin
authors.initials: A
authors.lastname: Rashidi
authors.affiliation: a Division of Oncology, Washington University School of Medicine , St. Louis , MO , USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Sorscher
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000209:etiology*; D018358:Neuroendocrine Tumors / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000077204:Temozolomide; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide